Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -34.80p -3.92% 853.60p 848.10p 852.30p 880.00p 850.10p 875.00p 48,634 09:44:38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 37.6 -11.8 -0.3 - 560.82

Oxford Biomedica Share Discussion Threads

Showing 105301 to 105325 of 105325 messages
Chat Pages: 4213  4212  4211  4210  4209  4208  4207  4206  4205  4204  4203  4202  Older
DateSubjectAuthorDiscuss
16/7/2018
09:05
Nothing telling about that Pram. I had no interest in repasting all of your nonsense. Just the bit I wanted to comment on. 'misjudged the potential and sold out before the rise' Well, that is misleading. I also sold out before the massive drop, but you leave that part out! There are hundreds of stocks that go up every day. I'm not remotely sad to miss out on one. Please just focus on commenting about OXB, rather than obsessively making remarks about one poster. You have your silly titled thread, where I don't post, so keep to there if you just want to read 100% positive back-slapping
stocktastic
16/7/2018
08:48
nearly down to the 50 SMA now but could drift further this week if no news or press coverage
bountyhunter
15/7/2018
20:01
From 2012 Bluebird`s Lentivector gives you an idea of what we are doing with Orchard/Novartis/Sanofi/Axovant etc. hTTps://www.youtube.com/watch?v=Ez560GnkSrE From 7 mins.
marcusl2
15/7/2018
19:31
Now, researchers have found that cancer stem cells exist in more than one state and are very plastic, meaning they can change form, sliding back and forth between a dormant state and a rapidly growing state. This plasticity is responsible for cancer's two key characteristics: multiplying and spreading. "When we use targeted therapies, they often only work for a certain period of time, and then the cancer becomes resistant. A lot of that resistance is from the cancer stem cells. They change form to evade the targeted therapy," says Wicha, Madeline and Sidney Forbes Professor of Oncology and director of the Forbes Institute for Cancer Discovery at the Rogel Cancer Center. "This tells us we're going to need multiple stem cell therapies to attack multiple forms of stem cells," he says. It turns out the cell metabolism controls this change, suggesting a possible way in to attack the stem cells. Cells get energy through mitochondria, which depends on oxygen, and through sugar, or glucose. Cancer stem cells pull energy both ways. In the dormant state, it uses glucose; in the proliferative state it depends on oxygen. So researchers attacked the metabolism in both ways. They used a drug currently used to treat arthritis that's known to block mitochondria, and they manipulated glucose to block that path. They tested this in mice with breast cancer and found they were able to knock out the stem cells. Results are published in Cell Metabolism. "Rather than just try to use toxic chemicals to kill a cell, we use the metabolism of the cell itself to kill the cancer," Wicha says. Researchers are also understanding that the immune system is regulated by metabolism, suggesting the possibility of combining anti-stem cell therapies with immunotherapies. Researchers hope to bring this concept to the clinic in the next few years. hTTps://medicalxpress.com/news/2018-07-metabolism-defeat-cancer-stem-cells.html
marcusl2
15/7/2018
19:10
hTTps://www.youtube.com/watch?v=uqcftz_RRts&feature=player_embedded Looking forward to hearing about the first patients being treated with Axo-Lenti-PD soon.
marcusl2
15/7/2018
10:38
"These are really exciting times. Anyone who has seen a CAR T cell patient respond with their tumor melting away in less than 4 weeks can see that this is truly astounding," said discussant David Maloney, MD PhD "Any new therapy is going to start in refractory patients. While we can get responses in completely refractory patients, it will likely be better if you can do this at an earlier time," hTTps://www.onclive.com/conference-coverage/cf-hem-2018/car-t-cell-therapies-offer-hope-for-dlbcl
marcusl2
14/7/2018
12:58
Yes, they are the sole manufacturer of the lentiviral vector that encodes Kymriah. It's just the completed article that will be produced in Europe...saves time in getting to the patients :-)
trovax
14/7/2018
12:04
Hi Trovax,regarding the CELLforCURE news - Does it mean that OXB will send the vectors to it, then CELLforCURE will deliver them to the cells? They are not taking up manufacturing lentivectors, are they? Looked at the company's website which is rather obscure, still not sure what it's role in CAR-T manufacture. Just wonder if OXB will be still the sole provider of the lentivectors? Thanks
kitty66
14/7/2018
09:22
An interview with Mr. Dawson.....follow the link for "Movers and shakers - it's in the genes" HTTPS://masterinvestor.co.uk/magazine/#
trovax
13/7/2018
22:35
hTTps://www.fiercebiotech.com/biotech/celgene-tweaks-trial-myeloma-car-t-bb2121-raising-dose?mkt_tok=eyJpIjoiWVdJeFltSTVNV0k1Wm1NeSIsInQiOiJSMnQ5Uk9xV3JnRmxIb0VNR01IbFlZd0g1b0UrRlQyMk1qYm82Sys3SG45b2l2UnpDS3NpelQ2TU0rXC9iSnc1SnF3Y0U1QU5ZdjNzeDBxTUY0ZXg2K0xaXC9NUEdrWjFHUEZXaUg2bTZXcUFyYUpOTW0xTllhMDlcL1NNNnNwVEtuZyJ9&mrkid=43024160
marcusl2
13/7/2018
22:07
Car T 5T4 has an effect on Cancer Stem Cells. Translation of Stem Cells to the Clinic: Challenges and Opportunities December 2–4, 2018 hTTp://www.cell-symposia.com/stem-cells-2018/_common/updateable/pdf/CS_StemCells_poster.pdf
marcusl2
13/7/2018
21:35
HTTPS://www.biopharma-reporter.com/Article/2018/07/13/Novartis-selects-French-CDMO-to-make-CAR-T-cell-therapies
trovax
13/7/2018
21:35
Look the share price will fluctuate. Sell a few when it spikes then buy back when it comes out from being oversold. It’s a pretty safe share. I’ve been in since about 4.5p
volsung
13/7/2018
21:30
Excellent post Harry. I reckon your recent purchase is a very sensible move.
marcusl2
13/7/2018
20:23
There's no need to apologise ewads, it's all fine. I wonder about lots of possibilities myself, not least because of the amount of money I have tied up in OXB these days. I always try to read the many links that Marcus posts here, but don't always have time to listen to / watch those with long presentations. Regardless though, I am aware (via those links) that there are better mousetraps in development which may (or may not) be eating into OXB's business in 5 years time. At the moment though, OXB is in good shape and this generation of technology will be around for a while. There are a handful of firms in the world who can tailor vectors and then manufacture in their own premises - OXB is one of them. What happens in 5 years time is certainly beyond my abilities as a hobbyist shareholder to forecast. To an extent we all have confirmation bias. Those of us who have held shares through the rise naturally want to think that we saw it coming and made the correct decision, but the reality is that everybody needs a little bit of luck - especially with timing of opportunity - else the cleverest people in the world would also be the richest. Someone who missed the rise with OXB might need to convince themselves that this is now only a short term fluctuation and that in the long term OXB is scuppered. But long term we are all dead and it's just unfair to assume that someone else's 5 year plan will work out, whilst the R&D department at OXB will produce nothing of use over the same period. I bought more shares on Monday. Probably not the most sensible thing to do as my portfolio is already out of balance, but I'm much more sold on OXB right now than I was back when it was 2p. So many boxes are ticked now and so many of my past worries addressed, that I'm happy to put a little more in. I plan on buying two more lumps this year and then that's probably me done. I just have a feeling that this time next year we will have posted our first full year profit and also have proved the qualifying period of share price at a particular level to go for the Nasdaq listing which we're all imagining the consolidation was to pave the way for. If JD can pull in a couple of deals in the second half of this year (based on the less than scientific rationale that he managed 2 in the first half), then that's quite a flotation document, isn't it? A bag full of recent deals, an ongoing commercial partnership with a massive multinational on their approved drug - and a set of last accounts with an audited profit. I wonder how many similar companies on that exchange make a profit.
harry s truman
13/7/2018
19:10
Sorry to infer negative tone! Thanks Harry
ewads
13/7/2018
16:50
Hi ewads, Marcus has linked to quite a few Carl June interviews here, so I can't easily point you to the relevant one. However, I can remember an interview where he gets asked almost exactly the same question and he replies with words to the effect that he has patients at 7 years, still being monitored, still with active CAR-T, still disease free and still going strong. Considering what these patients were facing (having failed on all best approved treatments) what is the reaction which, after 7 years of life these patients wouldn't have had, represents the opposite side of the coin? I think those reactions are the early ones (CRS etc) which are known about and well controlled now with complimentary drugs.
harry s truman
13/7/2018
16:32
I'm also pleased with progress. We all want instant success but it doesn't work that way.We waited many years for Prosavin to be marketed. The fact that being first approved in conjuntion with Kymriah, I can't help wondering whether there will be any reaction problems as we progress. (glass half full?). So far so very good.
ewads
13/7/2018
15:55
2 quick (and probably obvious) points:- For as long as I've held OXB it has fallen back in any quiet period which followed good news. This time it has taken a little longer to happen, but I don't think this behaviour is in any way unique to OXB. Even at this point it's still in the 17p range (in old money) when in real terms we had been in the 10p range for a long time prior to the recent news releases. I remain very happy with OXB's recent performance and am looking forward to what comes next (likely the EMA approval I think).
harry s truman
13/7/2018
15:47
Jasie, Re 1091 - No problems and I hope you get it sorted soon.
harry s truman
13/7/2018
14:23
Lull in share price surely just part of normal summer trading patter and retrenchment after stellar rise? No bad news so neither substantive nor likely to be sustained come third week of august or thereabouts.
beanol
13/7/2018
14:13
Very telling that when the_doctor reproduces my post from the other thread he misses off this paragraph.... "...in his case simply because he misjudged the potential and sold out before the rise. Contrast this with Proteome (PRM) thread where he admits to being a holder and posts positively, often without justification."
prambigear
13/7/2018
13:21
I am always intrigued by PI's seeking to guess the support level to the penny. The best chartists (of which I am not one) will use analytical tools developed to predict the range and potential break points which can be helpful to understand the trend. There are a multitude of reasons why OXB is fluctuating from its recent highs however the long term value and share price opportunity is very clear. I know short term gyrations can create a sell mentality however look how far we have come in few short months and a pipeline of new income streams that can only enhance the share price again.GLA
catch007
13/7/2018
13:09
"PramBigear 13 Jul '18 - 11:34 - 1094 of 1097 Sorry Lima Jane, but you completely misunderstand the reason this thread was set up. Criticism is fine, but continual posting of repetitive ‘information’ from a self confessed non-holder of these shares is simply an effort to trash the share" LOL Pram Your view is totally distorted - I don't feel a few honest and fair posts by a single poster to be something that will 'trash' a share. Many posters, as seen, commented that they valued alternative views, even if you don't. Most of the issue previously, was that a couple of individuals using the filter, continued to attack my every single post, without even being able to see them! They would make stuff up and post false accusations. Ignorant posters just blindly attack and fear what they don't understand, rather than providing intelligent, constructive responses. There is more fantasy bs posted by rampers than you would accept Remarks about 'non-holders' are silly when you consider that up to their eyeball holders post with a massive agenda
stocktastic
13/7/2018
12:44
FDA guidance; Human gene therapy for hemophilia: Gene therapy products for hemophilia are now being developed as single-dose treatments that may enable long-term production of the missing or abnormal coagulation factor in patients. This may reduce or eliminate the need for coagulation factor replacement. Once the draft guidance for hemophilia-targeted gene therapy is finalized, it will provide recommendations on FDA’s current thinking on clinical-trial design and preclinical considerations. Among other elements, the draft guidance provides recommendations regarding surrogate endpoints that could be used by sponsors pursuing accelerated approval. Human gene therapy for retinal disorders: Another area of fast-paced activity is gene therapy products targeted to the treatment of retinal disorders. hTTp://www.biopharminternational.com/fda-commissioner-gottlieb-releases-statement-advancement-gene-therapies OcQuila…………..Dr. Scribner spent 10 years at FDA hTTp://ocquila.com/
marcusl2
Chat Pages: 4213  4212  4211  4210  4209  4208  4207  4206  4205  4204  4203  4202  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180716 09:00:25